Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) was downgraded by equities researchers at Zacks Research from a "strong-buy" rating to a "hold" rating in a report issued on Thursday, Zacks reports.
ARCT has been the topic of several other reports. BTIG Research decreased their price target on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, September 24th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Thursday, September 24th. Citigroup raised shares of Arcturus Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $8.00 to $20.00 in a report on Thursday, September 24th. Roth Capital reissued a "buy" rating and issued a $41.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Arcturus Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $24.50.
View Our Latest Report on Arcturus Therapeutics
Arcturus Therapeutics Price Performance
NASDAQ:ARCT opened at $7.43 on Thursday. The stock has a 50 day simple moving average of $11.72 and a 200 day simple moving average of $9.10. Arcturus Therapeutics has a 1-year low of $5.50 and a 1-year high of $17.96.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.43. The firm had revenue of $18.30 million for the quarter, compared to analyst estimates of $8.00 million. Arcturus Therapeutics had a negative return on equity of 46.79% and a negative net margin of 285.92%. On average, research analysts forecast that Arcturus Therapeutics will post -2.94 earnings per share for the current year.
Hedge Funds Weigh In On Arcturus Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Arcturus Therapeutics during the 3rd quarter worth approximately $415,000. Entropy Technologies LP acquired a new position in Arcturus Therapeutics during the third quarter valued at approximately $767,000. Empowered Funds LLC acquired a new position in Arcturus Therapeutics during the third quarter valued at approximately $491,000. Tocqueville Asset Management L.P. acquired a new position in Arcturus Therapeutics during the third quarter valued at approximately $144,000. Finally, Kovack Advisors Inc. bought a new stake in Arcturus Therapeutics during the third quarter worth $144,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.
Arcturus Therapeutics Company Profile
(
Get Free Report)
Arcturus Therapeutics Holdings Inc. is a biotechnology company founded in 2013 and headquartered in San Diego, California. It develops RNA medicines and vaccines, using its LUNAR lipid-mediated delivery technology and self-amplifying RNA platform to deliver genetic instructions to cells. The company's pipeline includes investigational treatments for rare diseases, such as ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency. It has also developed ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved in Japan as Kostaive, and works with partners on the development and commercialization of its products.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.